Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First Real-world Data on Unresectable Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy

NCT03798535 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT03798535
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03798535 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First Real-world Data on Unresectable Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
December 19, 2018
Completion date
July 16, 2024
Enrollment
1,156 (actual)
Sites
254

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc